Thursday, June 30, 2022


Biotechnology News Magazine

Biotechnology News Magazine

Biotechnology News Magazine is one of the industry’s leading sources for biotech industry news!

Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.

Biotech executives, investors, and other allied health professionals have access to Biotechnology News Magazine through a complimentary subscription. Furthermore, as patients become more pro-active in researching various medical diseases and conditions, we are proud to boast they are subscribers of our publication as well.

We hope you find value in Biotechnology News Magazine’s overall purpose and objectives. BiotechnologyNews Magazine is the authoritative voice of biotechnology, bridging the industry to healthcare professionals, academia, government, venture capitalists, and the general public.

If you have any questions or comments, please feel free to contact us.

Biotechnology News Magazine is a fast, 1,2,3, easy read! LEARN MORE.

Latest Biotech Industry News

Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data

The technology licensed from Synaffix include GlycoConnect™, HydraSpace™, and multiple toxSYN™ linker-payloads, which allow for the drug-to-antibody ratio (DAR) to be tailored to 1, 2 or 4 to optimize the therapeutic index of the ADC.

MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines & Diagnostics for Chronic Metabolic Disease

MultiOmic Health advises the partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD notes the test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly.

NADMED Brings 1st CE-marked NAD+ Analysis Kit to the Market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites, allowing excellent accuracy comparable to mass spectrometry. Q-NAD kits use the same approach for the four NAD metabolites: NAD+, NADH, NADP, and NADPH.

H.E.L Group Releases iso-BTC+ Calorimeter for Isothermal Battery Performance Testing

The iso-BTC+ Calorimeter is designed to characterize thermal behavior and electrical performance of high power battery cells, highlighting regions of increased thermal energy generation and identifying risks of thermal runaway.

iNtRON Biotechnology to Seek a New Clinical Partner for SAL200 Endolysin

iNtRON Biotechnology said that SAL200, a endolysin-based novel antibacterial treatment for Staph superbugs including MRSA, has come back to the market and is now on-the table for an out-licensing deal.

Launch of Monkeypox Assay

The launch of this Monkeypox assay expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a global first responder in infectious diseases.

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain

ETX-810 is an investigational first-in-class, oral, non-opioid, new chemical entity (NCE) prodrug of the bioactive lipid palmitoylethanolamide

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

The paper, published in Kidney International Reports, describes observed improvements in renal function and a wide array of clinical parameters in patients with moderate to advanced diabetic chronic kidney disease treated with REACT™.

SIGA Technologies Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Procurement orders from new international jurisdictions have occurred as SIGA Technologies has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness.

Orange Grove Bio Provides Corporate Update

John C. Byrd, M.D. is named Chair of the Scientific Committee.

BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa

BioNTech notes the initial site will become a node in a decentralized and robust African end-to-end manufacturing network. All vaccines to be manufactured in the network will be dedicated to people residing in member states of the African Union.

Noteworthy Views & Opinions from Our Experts

Accelerate Diagnostics Automated Arc™ Blood Culture Kit and Module for Direct Identification of Organisms in Blood Cultures

Dr. Morgan writes, "Over the last four decades, clinical microbiology laboratories have utilized a variety of methods to biochemically identify organisms, beginning with tubed media, advancing to biochemical test strips and spot tests then automated biochemical panels," read what she has to say.

Making Antibody Drugs Available the World Over – By: Josh Eckman, CEO and Founder of Carterra

"We believe that innovation and competition will continue to push the boundaries of what is possible, leading to improved discovery timelines, lower costs, expanded access, and making it economically feasible to develop cures for more orphan diseases," writes Josh Eckman. He notes the company is developing tools that will drive the next wave of biotherapeutic discovery. Learn more.

Adi Zuloff-Shani PhD – It’s Time to Tackle Alcohol Abuse with Creative Solutions

Adi Zuloff-Shani PhD "Alcohol continues to fly under the radar as a legal substance that remains the country’s third most preventable cause of death, second only to smoking and obesity, with few effective treatment options. It’s a problem that cries out for solutions." What are those solutions? Read on to learn more.

FDA Updates

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with them to provide guidance on expediting the development and review process.

Acquisitions & Mergers

SPT Labtech Announces Acquisition by EQT Private Equity from Battery Ventures

EQT Private Equity will enable SPT Labtech to capitalize on this strong foundation of organic and acquisition-based growth and execute against an ambitious strategic vision for product innovation, geographic expansion, and targeting new end markets to address the evolving needs of the life science community.


Ingenza Awarded Government Funding

Ingenza advises the project aims to develop a novel CO2 conversion technology, which will capture industrial CO2 emissions and convert them into formate, a versatile chemical that can be used across various industries, including pharmaceuticals and agriculture.

Clinical Trials, Studies, Data

Avacta Announces 2nd Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein a (FAP) which is in high concentration in many solid tumours compared with healthy tissues.

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

The DiSCOVER trial is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy trial designed to evaluate EDSIVO™ (celiprolol) in patients with genetically confirmed COL3A1-positive vEDS using a decentralized clinical trial design and an independent adjudication committee.

Executives on the Move

Miguel Coego Rios Is Appointed CFO of CENTOGENE

Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company becomes effective June 22, 2022.

Marco Polizzi Appointed CEO of Paradigm Biopharmaceuticals Effective July 1, 2022

Marco Polizzi possesses over 30 years of experience in the pharmaceutical industry in various commercially focused roles, including creating new divisions within branded and generic pharmaceutical businesses.

HOOKIPA Executive Leadership Changes

HOOKIPA notes Katia Schlienger has been promoted to Executive VP, Clinical Development & Roman Necina, Chief Technology Officer, is appointed to the newly created role of Chief Development Officer.

Essentra Tapes Bolsters Global Sales Operations with Raft of New Appointments

Essentra Tapes has boosted its global operations with a raft of new appointments across its sales team around the world.

Market Reports

Health / Lifestyle Articles

Articles of Interest